A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)
Clinical trial NCT06081621 · COMPLETED
Trial details
- NCT number
- NCT06081621
- Sponsor
- Regend Therapeutics
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-11
- Primary completion
- 2025-03-14
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.